One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...